Editorial: Incorporating Phase 0 microdosing as a powerful tool into a new vision of drug development

• H. Markus Weiss,
• Yuichi Sugiyama,
• Yuichi Sugiyama,
• Esther van Duijn

Affiliations

H. Markus Weiss

Novartis Biomedical Research, Inc., Basel, Switzerland

Yuichi Sugiyama

iHuman Institute, Shanghai Tech University, Shanghai, China

Yuichi Sugiyama

Laboratory of Quantitative System Pharmacokinetics, Pharmacodynamics, Josai International University (JIU), Tokyo, Japan

Esther van Duijn

The Netherlands Organization for Applied Scientific Research, The Hague, Netherlands